Streetwise Reports' Article Archives — June%202022 back to current month (371)
New AI Solutions Set To Transform Medical Education and Clinical Practice (04/19/2024)
Treatment.com AI Inc., a leader in artificial intelligence for healthcare education, has introduced two new tools for its Medical Education Suite (MES).
Analyst Says Pharma Co. Has No True Competitor (04/19/2024)
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.
LA Biotech's Lower Revenue Will Be Short Lived (04/17/2024)
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.
Healthcare Co. Welcomes Possible AI Funding Effort in Canada (04/09/2024)
Canadian artificial intelligence (AI) and machine learning healthcare company Treatment.com AI Inc. is using AI to positively disrupt the healthcare sector. Canada is planning to fund the industry in a big way.
Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out (04/08/2024)
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.
Co. Adding 500 Patients to Its Mental Health Care Platform (04/03/2024)
This Canada-based health care technology firm is profitable and growing. Learn more about it here.
Analyst Encouraged by ON Gov's Decision To Sustain Fees (04/02/2024)
CareRx Corp. will continue to receive funding for professional fees at the same levels as before for at least one more year, according to a Leede Jones Gable research note.
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock (03/27/2024)
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.
AI Co. Funded To Develop AI Approach to Health Equity (03/27/2024)
Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock.
AI Medical App Passes Standard Student Test (03/26/2024)
This software is one of a suite offered by this health care technology firm. Learn about its other products and the growing sector.
Healthcare Stock Has Reasonable Value Before Seasonal Profit, Analyst Says (03/26/2024)
K-Bro Linen Inc.'s FQ23 financial data supported its Buy rating, according to a Leede Jones Gable research note.
Biotech Co.'s Target Price Significantly Higher Than Current (03/19/2024)
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.
Biotech Stocks Break Out (03/19/2024)
Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into.
Is This Pharma Set To Break Out After COPD Drug Approval? (03/15/2024)
Clinical-stage biopharmaceutical company Verona Pharma Plc is looking toward a pivotal year as its new chronic obstructive pulmonary disease (COPD) drug ensifentrine nears possible approval by the FDA. At least two research companies have named it a top pick for 2024.
This Biotech Is a Potential Disruptor, Expert Says (03/12/2024)
Chris Temple of The National Investor shares why he believes BetterLife Pharma Inc. is an Immediate Buy.
Wellness Co.'s New Initiatives Should 'Lower Barriers' Analysts Say (03/12/2024)
The Beachbody Company Inc.'s 4Q23 results have Roth MKM analysts maintaining their Buy rating.
Safe Supply Firm Announces Another Promising Acquisition (03/11/2024)
Safe Supply Streaming Co. adds another company to its portfolio, and continues advocating for harm reduction in the psychedelic sector.
Healthcare AI Firm Has 'Bright Future,' Analyst Predicts (03/08/2024)
Canadian artificial intelligence (AI) and machine learning healthcare firm Treatment.com AI is breaking into the global healthcare AI market predicted to be worth US$187 billion by the end of the decade.
NY Biotech Has Potentially Game Changing Anxiety Therapy (03/07/2024)
Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note.
Bionic Medical Co. Has Sufficient Funds to Operate Through 2024 (03/05/2024)
Ekso Bionics Holdings Inc.'s fourth quarter of 2023 financial results were in line with estimates, according to H.C. Wainwright & Co.
'Safe Supply' Co. Secures Legal Flow of Coca Products (02/20/2024)
This is a milestone for the venture capital firm investing in efforts that address the toxic drug crisis in Canada and the U.S. Learn more about the company and the latest wave of drug reform.
Alt-Pharma VC adds 7% Stake in Testing Strip Firm (02/15/2024)
Alt pharma is hot these days, and few companies are coming in hotter than Safe Supply Streaming Co. Ltd., which just secured a 7% stake in a leading medical test company to expand its functional portfolio.
Cash Rich Biotech Could Win a Lawsuit With Lilly, Expert Says (02/12/2024)
Ron Struthers explains how the cash value of this biotech is about $1.68/share and the stock is selling at around -58% discount to cash value. He also discusses a recent lawsuit with Eli Lilly.
Wellness Co. Preparing for US Legislation (02/12/2024)
Wellness company Canopy Growth Corp. is taking steps forward while it waits for the U.S. to make legislative changes, according to a Roth MKM research note.
Drug Reformer Subsidiary Inspected for Dealer License (02/02/2024)
In a "transformative moment" for the company, a Safe Supply Streaming Co. Ltd. subsidiary has undergone an official inspection by Health Canada to acquire a dealer license to produce, distribute, and export controlled substances.
Leadership Cuts Won't Slow This Biotech (01/26/2024)
While three executive officers have been cut from Kronos Bio Inc., it is still a Buy, according to an H.C. Wainwright & Co. report.
Pharma Co. Primed for Future Business (01/25/2024)
Analysts at Research Capital believe that Knight Therapeutics Inc. is primed to conduct future business development.
Healthcare Co. Exceeds Expectations in Performance (01/24/2024)
Sensus Healthcare Inc. released fourth-quarter financials that surpassed expectations, according to an H.C. Wainwright & Co. research note.
Innovator in Drug Policy Now Listed on the OTCQBA Venture Market (01/18/2024)
Safe Supply Streaming Co. Ltd. Announced that it is expanding availability for potential investors. Read on to see why this stock might represent an opportunity as drug policy changes.
Pharma Co. Invests in Clinical Psychedelics (01/17/2024)
ATAI Life Sciences N.V. has announced that it is investing in psychedelic treatments for Major Depressive Disorder and Alcohol Use Disorder. Read on to see why one analyst likes this company's stock.
Money Manager: The Year of Small Caps? (01/16/2024)
The president and chief executive officer of Toronto-based AlphaNorth Asset Management says his positive outlook on 2024 has not changed. In fact, it could be a great year for small caps.
Big Pharma's Looming Patents May Benefit One Biotech (01/10/2024)
Pharma stocks took big hits in recent years as many of its largest companies saw a looming "patent cliff" that could dry out profits from their big cash-cow drugs. This may be good for smaller pharma companies like one stock, which was one of Chen Lin's top picks for 2024.
Biotech Co.'s Sales Could Grow To US$310 Million in 2028 (01/10/2024)
Biotech Valneva SE announced that it had dosed the first participant in a Phase 2 pediatric trial evaluating its chikungunya vaccine candidate, according to an H.C. Wainwright & Co. report.
Telehealth Co. Adding Thousands to Large Contract (01/10/2024)
Reliq Health Technologies Inc. has signed a contract expansion with a large U.S. health plan, possibly adding as many as 50,000 new patients to its iUGO telehealth platform.
2024: Chen Leads With Biotech After Picking 2023's Top Stock (01/05/2024)
Asset manager Chen Lin was very happy with his picks from 2023, including one that ended up soaring 1,900%. See what the asset manager has lined up for the new year.
Market Correction and One Cash Rich Biotech (01/03/2024)
In late December, Ron Struthers pointed out that the S&P 500 made a double top and showed numerous over-bought conditions, so a correction is expected. He also shared one biotech that has been whacked down way below its cash value.
Boston Biotech Could Have Blockbuster Sales (01/03/2024)
Tango Therapeutics may have "blockbuster potential," noted an H.C. Wainwright & Co. report.
Pharma Co. Gets First US Patent for Repurposed Drug (01/02/2024)
Clinical-stage pharmaceuticals firm Algernon Pharmaceuticals Inc. has been issued a U.S. patent for the treatment of three related diseases with its investigational drug repirinast.
California-Based Pharma Co.'s Progress Offers Upside (01/02/2024)
While H.C. Wainwright & Co. lowered their price target, they still see upside for this pharmaceutical company.
Contracts Add Thousands of Patients to Telehealth Platform (12/28/2023)
Reliq Health Technologies Inc. says it has signed new contracts with 10 physician practices in three states to add thousands more patients to its iUGO telehealth platform.
Co.'s Breast Cancer Therapy Shows Encouraging Activity (12/28/2023)
BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report.
Biotech Secures Additional Funding, Extending Cash Runway (12/27/2023)
Recently, Vera Therapeutics Inc. announced it had further strengthened its balance sheet by drawing down US$25 million in debt, bringing total cash reserves to US$159.9 million, noted H.C. Wainwright & Co.
Biotech Bolsters ADC Pipeline Through Atreca Asset Buy (12/26/2023)
Biotech Immunome Inc. recently announced a purchase agreement with Altreca, noted Wedbush.
US Biotech's Anti-Fungal Wins European Approvals (12/22/2023)
Recently, Cidara Therapeutics Inc. secured European Commission (EC) approval for its lead anti-fungal candidate Rezafungin to treat invasive candidiasis infections in adults, noted H.C. Wainwright & Co.
Biotech Co. Reports Encouraging ALS Data but FDA Wants More (12/21/2023)
Salt Lake City-based Clene Inc. reported both encouraging clinical data and a regulatory setback for its ALS drug candidate CNM-Au8, reported Roth MKM.
Pharma Co. May Have Accelerated FDA Approval in 2024 (12/20/2023)
TRACON Pharmaceuticals Inc. provided an update on enrollment progress for their ongoing Phase 2 ENVASARC clinical trial testing the drug envafolimab to treat sarcoma, reported H.C. Wainwright & Co.
Lithium Co. Will Be a Substantial Outperformer (12/19/2023)
Michael Ballanger of GGM Advisory Inc. shares a quick note about why he has faith in Volt Lithium Corp.
Bioscience Co. Expands Collaboration (12/19/2023)
This bioscience company's price target implies 680% upside, according to a Roth MKM report.
Promising Biotech Selling Way Under Cash Value (12/18/2023)
Nkarta is using CRISPR technology for cell therapies for leukemia. The FDA just approved a similar cell therapy treatment for Vertex using the same CRISPR technology. Nkarta is trading well below cash value and has a significant short position sinking underwater.
Texas Biotech Advances Lead Candidate in Resistant AML (12/14/2023)
Recently, Texas-based biotech Bio-Path Holdings Inc. announced it had completed the first safety cohort of a Phase 1/1b trial evaluating the developmental drug BP1002 in acute myeloid leukemia (AML). Read on to see what one Roth analyst has to say about the company's stock.
Biotech Seeks Approval of Synthetic Blood Vessel Graft (12/12/2023)
Humacyte Inc. announced the submission of a Biologics License Application (BLA) to the FDA seeking approval for its lead product candidate Human Acellular Vessel (HAV), noted H.C. Wainwright & Co. Analyst Vernon Bernardino.
Drugs Show Anti-Cancer Effects on Myeloma Cells (12/06/2023)
These positive results bode well for the biopharma's two polyamine inhibitors as potential treatments for multiple myeloma, noted a ROTH Capital Markets report.
Antibodies from Vaccine Remain Two Years Out (12/06/2023)
This was shown in recent clinical trial results of a biotech's single-dose vaccine against chikungunya evaluated in adults, noted an H.C. Wainwright & Co. report.
Pharma Co. Reports Positive Data for Leukemia Combination Therapy (12/06/2023)
Recently, Syros Pharmaceuticals Inc. announced positive data for its Leukemia Combination Therapy, noted an H.C. Wainwright & Co. report.
Massachusetts Biotech Plummets as Skin Cancer Trial Fails (12/05/2023)
In recent news, Massachusetts clinical-stage biotechnology company Replimune Group Inc. revealed its latest clinical trial did not meet the endpoints needed to call it a success. With this, the stock has plummeted.
Pharma Co.'s Partnership a Key Validation (12/04/2023)
Recently, Arcus Biosciences Inc. announced a partnership with Exelixis Inc., which may be the key to validating the company, noted WedBush analysts in a December 4 report.
Biotech Announces New Responder in Breast Cancer Trail (11/30/2023)
Recently, BriaCell Therapeutics Corp. announced a new exceptional responder in its Phase 2 study evaluating the company's off-the-shelf personalized immunotherapy, noted H.C. Wainwright analyst Emily Bodnar.
Biotech Receives First Approval; Drug Now Available (11/28/2023)
Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results, noted H.C. Wainwright & Co. analysts Robert Burns and Dr. Raghuram Selvaraju.
Encouraging Early Data For Biotech's Cancer Therapies (11/21/2023)
In a recent corporate update, Purple Biotech Ltd. reported positive interim Phase 1/2 data for NT219 and accelerated enrollment for CM24, noted H.C. Wainwright analyst Emily Bodnar.
Strong Early Launch Metrics for Biotech's Skin Disease Drug (11/20/2023)
Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment.
Arizona Biotech Advances Multiple Cell Therapies (11/16/2023)
Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline, including upcoming Phase 1/2 data.
Massachusetts Biotech Advances Novel Cytokine Therapies (11/15/2023)
Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and pipeline, according to a WedBush research note.
Massachusetts Biotech Presents Catalysts Into 2024 (11/08/2023)
Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten.
Texas Biotech Exceeds Alzheimer's Trial Enrollment Target (11/08/2023)
This Texas-based biotech company's enrollment in its two pivotal Phase 3 trials evaluating lead drug candidate simufilam for Alzheimer's disease surpassed initial enrollment targets, noted H.C. Wainwright analyst Vernon Bernardino.
Expert Shares Thoughts on Six Stocks (11/07/2023)
Chris Temple of The National Investors shares a detailed report on stocks from the life science to the energy sector to tell you which he believes are Buys and which you should sell.
Biopharma Acquires Royalty on Approved Diabetes Drug (11/03/2023)
This is one of the California-based company's many transactions resulting from its royalty monetization strategy, noted an H.C. Wainwright & Co. report.
Survey Results Positive for New HAE Drug (11/02/2023)
Most responding physicians, all with hereditary angioedema patients, indicated an "above average" impression of the treatment's safety and efficacy data, noted an Oppenheimer report.
Safety Profile of New IL-2 Molecule Better Than Like Drugs' (11/02/2023)
First clinical data of this investigational interleukin-2 cytokine show it lacks the degree and rates of adverse events typically seen with treatments of this kind, noted an H.C. Wainwright & Co. report.
Firm To Present Trial Results Update at SITC Meeting (11/02/2023)
Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report.
Add Back Positions in This Biotech (11/01/2023)
Chris Temple of The National Investor shares one stock he believes is currently a Buy, as a gross overreaction caused sell-offs.
Biotech to Advance New Type 1 Diabetes Drug Into Clinic (10/23/2023)
Dosing of the first patient is expected in Q4/23 in this Phase 1 trial to be done in Australia, noted an H.C. Wainwright & Co. report.
Approval Likely in U.S., EU for New Drug for Prader-Willi (10/12/2023)
Despite recent positive clinical trials, the biopharma behind this treatment remains undervalued presenting a buying opportunity, noted an Oppenheimer report.
Drug Reform Streaming Co. Starts Trading on CSE (10/12/2023)
This company investing in and incubating companies at the forefront of drug policy reform has started trading on the Canadian Securities Exchange. One writer says buying stock is a chance to be a part of a "movement."
Diagnostics Biotech Beats Revenue Estimates in Q3/23 (10/11/2023)
The Belgium-based company is well on its way to achieving, and possibly exceeding, full-year revenue guidance, noted an Oppenheimer report.
Chen Still Likes This Precious Metal in Q4 (10/09/2023)
If you've been following asset manager Chen Lin's quarterly picks on Streetwise Reports, you know he is bullish on one particular precious metal, and the fourth quarter of 2023 is no exception.
Trial of New Drug for Acute Leukemia Meets Primary Endpoint (10/05/2023)
The biopharma behind it plans to submit a new drug application, seeking approval of the compound, by year-end, noted an H.C. Wainwright & Co. report.
New CAR-T Therapy Shows Potency in Certain Patients (10/04/2023)
Study results for patients with relapsed/refractory multiple myeloma continue to be "favorable," noted a ROTH Capital Partners report.
New Contract Adding Thousands of Patients to Telehealth Platform (09/27/2023)
This telehealth company has signed a contract with a physician network to add as many as 100,000 patients to its platform. Find out why the CEO says it is in a period of rapid growth.
Biopharma Co. Adds CTO to Team (09/21/2023)
This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report.
Trial Results Validate New Drug-Delivering Nasal Implant (09/20/2023)
This product candidate presents a compelling approach to treating post-surgery chronic rhinosinusitis patients, noted an H.C. Wainwright & Co. report.
Biotech Co. Makes Strides on Three Fronts (09/19/2023)
This Canadian firm sold assets, launched an equity raise and filed a clinical trial application for its lead psychedelic-assisted psychotherapy program, noted a Stifel report.
Telehealth Co. Signs Contract With Client in Eight States (09/13/2023)
This telehealth company has signed a new contract for its remote patient monitoring platform to be used by a leading healthcare company with dozens of locations in eight states.
Telehealth Co. Expands Platform To Cover Pediatric Patients (09/08/2023)
This telehealth company is expanding its platform to cover remote monitoring for pediatric patients with diabetes and other eligible conditions. Find out why one analyst says this company's stock is gathering momentum.
Co. Reaches Major Milestone With Novel Drug (09/07/2023)
The biopharma initiated enrollment of a targeted 420 patients for one of its Phase 3 clinical trials evaluating its new cardiac myosin inhibitor, noted an H.C. Wainwright & Co. report.
Cryoablation System Gets Approved in Brazil (09/07/2023)
The product developer expects to generate US$6.6 million in sales of this medical device in Brazil over the next five years, noted an H.C. Wainwright & Co. report.
After Seeing 86% Success Rate in Phase 2, Biotech Co. Moves to Phase 3 for AUD Treatment (09/06/2023)
Awakn Life Sciences has applied for Phase 3 of clinical trials after the success of Phase 2. Read on to see what this company plans for its flagship new drug.
FTC Settles Suit, Potentially Averting Further Hurdles (09/06/2023)
McAlinden Research shares a deep dive into a market driver with alpha-generating potential.
Contract Adding Thousands of Patients to Co.'s Telehealth Platform (09/05/2023)
This telehealth company has signed a new contract with a Texas respiratory clinic that is expected to add 10,000 new patients to its iUGO platform by mid-2024. Read to see why one analyst believes this stock is a Buy.
New Vaccine for Chikungunya Shown To Be Safe in Youths (09/01/2023)
The company behind the vaccine plans to use the safety data to support approvals in the U.S., European Union and Brazil, noted an H.C. Wainwright & Co. report.
Approved Drug for Skin Condition Shown Safe at Higher Dose (09/01/2023)
Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report.
Canadian Veterinary Co. Revenue Increased to CA$12.7 Million in First Half of 2023 (08/31/2023)
Grey Wolf Animal Health Corp. has announced the financial results of the last quarter. Read on to see why one newsletter writer believes this stock is worth looking into.
Catalyst Rich 12 Months Ahead for U.S. Biopharma Co. (08/29/2023)
Investors can expect to see new drug application filings, a PDUFA meeting outcome, clinical trial results and revenue stream additions, noted a ROTH Capital Partners report.
DNA Tech Co. Launches MRNA Platform and Files Two Patents (08/29/2023)
This company has announced the general availability of its Linea IVT platform evaluation kits and the first kit shipment to an existing Linea IVT Template customer. It has also filed two provisional patent applications for its technologies to reduce the impurities and decrease manufacturing costs for mRNA therapies like some COVID-19 vaccines. Read to see what experts are saying about the stock.
FDA Approves New Oncology Drug for Clinical Trials (08/28/2023)
The first in-human trial of this investigative small molecule is expected to start in Q4/23, noted a Wedbush report.
Telehealth Co. Launches Monitoring Program for Acute Patients (08/18/2023)
Reliq Health Technologies Inc. has launched a new post-discharge program for acute care hospitals on its iUGO platform and signed contracts in California, Florida, and Puerto Rico.
Co. Still Undervalued Post Solid Q2/23 (08/16/2023)
The multistate operator is on a growth trend and just raised its free cash flow guidance for the year, noted a ROTH Capital Partners report.
Med Tech Firm's Q2/23 Revenue Beats Target (08/10/2023)
The company is expected to gain greater market share in one segment of its business, warranting a price target increase, noted a ROTH Capital Partners report.
Telehealth Co. Inks Contracts With Rural Clinics in 5 States, Territories (08/09/2023)
Telehealth company Reliq Health Technologies signs contracts with 20 new rural health clinics (RHCs) in California, Nevada, Puerto Rico, Texas, and the U.S. Virgin Islands.
The Bond Market Has the Blues, Oil Breaks to the Upside and Moderna to the Downside (08/07/2023)
The long end of the bond market is starting to price in sticky inflation, and Ron Struthers of Struthers' Stock Reports expects interest rates to rise further. Higher energy prices will start adding to inflation again, adding to the problem. Moderna has broken down on the chart and will be reporting red ink in the next few years. Time to go short.
Biotech Co. An Attractive Investment (08/04/2023)
Technical Analyst Clive Maund reviews Awakn Life Sciences Corp.'s 26-month and year-to-date charts to tell you why he believes it is an attractive investment.
Telehealth Co. Continues To See Soaring Revenues (08/02/2023)
This telemedicine company just had its first profitable quarter, and now it could see revenues double twice over two fiscal years.
Co. Works to Strengthen Itself After Merger Ended (08/02/2023)
Its efforts include restructuring debt and divesting assets, noted a ROTH Capital Partners report.
Merger Between Two Firms Called Off (08/02/2023)
The deal broke down because the parties could not sell assets that had to be divested for it to go through, noted a ROTH Capital Partners report.
Co. Starts Using AI on Its Telehealth Platform (07/21/2023)
This telehealth company says it has started using artificial intelligence (AI) and machine learning (ML) with two of the clients on its platform.
Second Half of 2023 Is Catalyst Rich for This Biopharma Co. (07/19/2023)
The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant depression, noted an H.C. Wainwright & Co. report.
Top Pick Healthcare Technology Co. Trading at Deep Discount (07/19/2023)
The healthcare tech firm's shares are underperforming despite two consecutive record quarters and a "landmark" contract win, noted an Echelon Capital Markets report.
Healthcare Tech Firm Sells Noncore Assets for $6M (07/10/2023)
The resulting upfront valuation gain equates to an estimated $0.02 per share, noted an Echelon Capital Markets report.
Approval Sought in Japan for New SARS-CoV-2 Vaccine (07/07/2023)
The vaccine developer's partner in Japan is already working on getting a manufacturing facility built there, noted an H.C. Wainwright & Co. report.
Co. Addresses Opioid Crisis Through Novel Platforms (07/07/2023)
This California biotech, developing products that prevent opioid abuse and overdose, gained coverage by an H.C. Wainwright & Co. analyst, an initiation report noted.
Up to 10,000 Patients To Join Telehealth Co.s Platform in Mexico (07/06/2023)
This company is expanding its telehealth platform into Mexico, where more than 10,000 new patients are expected to be on board by next June.
New Psoriasis Drug Shown More Effective Than On-Market One (07/06/2023)
Recent clinical trial results show the oral interleukin-23 receptor to be a "cleaner" target than non-receptor tyrosine kinase 2, noted a BTIG report.
Co. With Alzheimer's App 'Meaningfully Undervalued,' Analyst Says (07/05/2023)
Despite having revenues below expectations, one analyst says this health company's Alzheimer's dementia diagnosis app is gaining commercial traction.
Biotech Co. Remains Opportunity for Those With High Risk Tolerance (06/30/2023)
Recently, Antibe Therapeutics released its fiscal 2023 year-end (FQ423) results, which remained inline with expectations, noted an Echelon Capital research note.
Q3: Chen Is Still Bullish on This Precious Metal (06/29/2023)
Asset manager Chen Lin continues to rely heavily on this precious metal. Find out his top picks for the third quarter of 2023.
Telehealth Co. Expands to More Patients, Picks Up Coverage (06/26/2023)
Reliq Health Technologies Inc. continues to pick up more contracts with skilled nursing facilities (SNFs) and other health care groups. Now it also has gotten analyst attention.
New Drug for Bone Growth Disorder Improves Height Velocity (06/21/2023)
Phase 2 trial data at six months are positive in children with achondroplasia, noted a BTIG report.
Biotech Co. Completes Step Toward Psychedelic Treatment for Brain Injuries (06/16/2023)
Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream.
777% Gain Implied in Analyst's Target Price on Biopharma Co. (06/14/2023)
Results from a Phase 2 trial of this U.S. company's cystic fibrosis drug are due out next month, noted an H.C. Wainwright & Co. report.
Telehealth Co. Expands With Six New Contracts in Three States (06/13/2023)
New contracts are expected to add more than 3,000 new patients to Reliq Health Technologies Inc.'s platform by the first quarter of next year, the company said.
Court Grants Firm Protection From Creditors (06/12/2023)
Despite this development, there are still some ways this Canadian retailer-distributor could salvage some value for shareholders, noted an Echelon Capital Markets report.
Biotech Co. To Exit Health Care Services (06/12/2023)
Friday, Awakn Life Sciences Corp. announced it would be taking focus away from healthcare services and instead concentrate its efforts exclusively on research and development for therapeutics for addiction treatment. Read more to learn what the global addiction treatment market looks like and where the company is headed in the future.
Key Catalyst for US Biopharma Stock on Track for Q4/23 (06/09/2023)
Readout of a Phase 2b trial is expected then, and positive data could support approval of the company's drug candidate, noted an H.C. Wainwright & Co. report.
Medical Device Co. Completes Merger in Q1/23 (06/08/2023)
Due to the acquisition, the U.S.-based firm generated 844% more revenue during the quarter than it did a year earlier, noted a Ladenburg Thalmann report.
Healthcare Tech Firm Grows Revenue 10% YOY in Q1/23 (06/05/2023)
This positive start to 2023 bodes well for the company turning EBITDA positive later this year, which is expected, noted an Echelon Capital Markets report.
FDA Approval, Private Placement Funding Buoy Biotech Firm (06/05/2023)
Krystal Biotech Inc. appears to be picking up steam for the year's second half. The company's Vyjuvek topical gel for treating Dystrophic Epidermolysis Bullosa (DEB) was approved by the FDA on May 19, leading to a major funding announcement.
Telehealth Co. Notches First Profitable Quarter (06/02/2023)
Reliq Health Technologies announces record revenues for the three months ending March 31 and its first profitable quarter after a loss during the same quarter in 2022.
Analyst Says Pharma Co. 'Meaningfully Undervalued' (06/01/2023)
"We continue to view Mindset as meaningfully undervalued," Stefan Quennevill reported in an Echelon Capital Markets research note.
U.S. Firm's Earnings To Remain Robust Through 2023 (05/25/2023)
Recent and upcoming events, including new store openings, will drive sales and revenue growth for this retailer and wholesaler, noted an Echelon Capital Markets report.
Animal Feed Company Evaluating Strategic Alternatives (05/23/2023)
Avivagen is considering strategic plans to maximize value to shareholders. Read more to see what the possibilities may be for shareholder profit.
Wellness Co.'s Q1/23 Results Better Than Expected (05/19/2023)
Results for the first quarter of this year for Ayr Wellness Inc. were better than expected, reported an Echelon Capital Markets research note.
Telehealth Co. Signs Contract With US Health Plan Serving 1 Million Patients (05/18/2023)
Telehealth company Reliq Health Technologies signs a contract with a U.S. health plan that operates in five states with over 3,000 doctors and more than 1 million patients.
Biopharma Co. Ceases Program to Optimize Resources (05/16/2023)
This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report.
Digital Health Co. Grows Revenue and Reduces Expenses (05/10/2023)
This Canadian healthcare tech company is showing projected returns of over 241% for investors, noted an Echelon Capital Markets research note.
Telehealth Co. Expands into Arkansas (05/05/2023)
Telehealth company Reliq Health Technologies signs five new contracts in four states for its iUGO platform, including its first contract in the state of Arkansas, where chronic diseases cost billions annually.
Pharmaceutical Company Sets Gold Standard for New Drugs (04/26/2023)
Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history.
Adding Silver a Solid Move (04/24/2023)
Michael Ballanger of GGM Advisory Inc. reviews the state of the SPX Index, the gold-to-silver ratio, and the current lithium market.
As Countries Bolster Defense, Opportunities Emerge (04/21/2023)
Defense stocks are uniquely positioned to enjoy considerable, reliable funding from government contracts. This stability, and the ensuing profitability, increases during times of international political instability.
Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial (04/19/2023)
Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill.
Co.'s New Cell Therapy Shows Positive Effects (04/19/2023)
Disease response and survival rates are impressive in updated results from several studies, noted an H.C. Wainwright & Co. report.
Blockchain Co., Vets Group Team Up for App (04/19/2023)
A Vancouver blockchain company is partnering with a leading veterans advocacy group to launch a medical cannabis education and reward application for vets.
Oncology Co. Receives Buy Rating for New Drug Trials (04/18/2023)
A California drug company is moving into new phases of drug trials targeted at solid tumors, noted an H.C.Wainwright & Co. report.
Biotech Rated Outperform Advances Top Drug Candidate (04/18/2023)
The biotech launches another trial of its KIT inhibitor and reports preclinical data for other inhibitors in its pipeline, noted a Wedbush report.
Trial Results of New Pneumococcal Vaccine Compelling (04/18/2023)
Data show the vaccine elicited better immune responses in adults ages 50 and up than the standard of care vaccine, noted a BTIG report.
Follow-up Results From T2 Diabetes Trial Positive (04/14/2023)
One year out, overall efficacy was 93% in the patients treated with a new autologous immunotherapy, noted a ROTH Capital Partners report.
CEO: Telehealth Co. in 'More Comfortable Cash Position' (04/14/2023)
Telehealth company Reliq Health Technologies Inc. expects to be profitable for the quarter ending in June and initiate a share buyback program this year, its CEO told shareholders this week.
Biotech Co. Set To Reach New Highs (04/13/2023)
Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics.
Phase 3 Trial in Progress of New Ichthyosis Treatment (04/12/2023)
Patient recruitment is 50% complete for this multicenter study evaluating a designated orphan drug as treatment for these congenital disorders, noted an H.C. Wainwright & Co. report.
Biopharma Co. Appoints Industry Experts in Key Positions (04/11/2023)
Recently, Appili Therapeutics Inc. (APLI.TSX) appointed a new director of non-clinical research and director of new product development. Read to see who these people are, what upcoming catalysts there are for the company, and what experts are saying.
Phase 2b Trial of New Drug for Ovarian Cancer Starts (04/11/2023)
The investigative, novel small molecule is the lead drug candidate for this U.S. biopharma developing treatments for serious oncological conditions of unmet medical need, noted an H.C. Wainwright & Co. report.
Safety Data From One Trial of New Drug Helpful to Another (04/05/2023)
The investigative compound is atrasentan, currently under evaluation in a Phase 3 study as a treatment for nephropathy, noted an H.C. Wainwright & Co. report.
Biotech Co. Will 'Not Look Back' From Here (04/05/2023)
In light of its recent development of a product that purportedly has the ability to reset damaged DNA, technical analyst Clive Maund takes a look at Resverlogix Corp.
Firm Grows Revenue 38% in Q4/22 (04/04/2023)
The company's material increase in profitability during the quarter is a healthy step toward reaching free cash flow break even status, noted an Echelon Capital Markets report.
Target Price on Texas-Based Drug Co. Implies 1,929% ROI (04/04/2023)
This biopharma expects two major catalysts, in the form of Phase 2 clinical trial data readouts, this year, noted a ROTH Capital Partners report.
Resverlogix Testing Cure for Covid, the Terrible Spike Protein and Heart Issues (04/03/2023)
In light of Resverlogix Corp.'s testing of a cure for long Covid, Bob Moriarty of 321gold.com reviews the company to tell you why he believes it may be a Buy.
New Treatment for Ovarian Cancer Shows Promise (03/30/2023)
Additional trial data also show efficacy of this investigative combination treatment in a difficult to treat patient population, noted an H.C. Wainwright & Co. report.
Telehealth Co. Signs Largest Client Yet (03/30/2023)
Onboarding will begin in April for the healthcare system that has more than 1,200 care centers in seven states.
Coverage Launched on Drug Co. With 140% Upside (03/29/2023)
The Canadian specialty pharma, with a proven track record of in-licensing and acquiring late-stage assets, is "poised to grow meaningfully in the coming years," noted an Echelon Capital Markets report.
Trial of New Ophthalmic Drug Now Enrolled (03/29/2023)
More than the target number of patients was enrolled in this Phase 2 study of an investigative treatment for a serious eye disease, noted an H.C. Wainwright & Co. report.
FDA Approval of New Gout Drug Likely, Analyst Says (03/27/2023)
Despite a competitor already on the market, the commercial opportunity for this particular treatment is strong, given its advantages, noted a BTIG report.
Biotech Improves Efficiency of Its New Immunotherapy (03/22/2023)
The enhancements the company made to its investigative therapy that uses a patient's own immune cells were independently validated, noted a ROTH research report.
Former NFL Safety Director Joins Neurotherapy Firm Advisory Board (03/21/2023)
Treating traumatic brain injury with alternative pharmaceuticals is delicate work. Now one Canadian firm has enlisted the help of former National Football League Neurological Player Care Safety Director Dr. David Brody.
Coverage Launched on Canadian Specialty Pharma Co. (03/15/2023)
This company can further grow its product portfolio and revenues and, thus, boost its operating leverage, but these capabilities "remain underappreciated by investors," noted an Echelon Capital Markets report.
Telemedicine Co. Sees Record Revenues on Software, Services Sales (03/13/2023)
Reliq Health Technologies Inc. reports that software and services revenue continues to increase, leading to record cash intake for the quarter that ended Dec. 31, 2022.
Blockchain Co. Launches Digital Coupon Consumer App (03/08/2023)
Global Compliance Applications Corp. is launching a new app that will enable consumers to receive and share digital token coupons and store them in digital wallets.
New Skin Gene Therapy Gets PDUFA Date (03/01/2023)
The future of this investigational treatment for dystrophic epidermolysis bullosa looks positive, with full approval and subsequent successful commercial launch expected, noted an H.C. Wainwright & Co. report.
Novel Therapy Corp Captures More of US Licensing Market, First EU Segment (02/28/2023)
White-label reselling of proven therapeutic compounds and concepts to existing, branded providers offers research companies a way to capture market share without marketing expenses – or other customer-facing costs. Awakn Life Sciences Corp., already a marquee name in rehabilitation clinics across Europe, is also rapidly engaging in this lucrative secondary profit stream.
AI-Infused Telehealth Platform Absorbs New Patients (02/22/2023)
Telemedicine company Reliq Health Technologies Inc., which uses artificial intelligence in its software's algorithms, has gained six new contracts and more than 3,000 new patients.
Biotech Co. Initiates Feasibility Study (02/09/2023)
This morning Awakn Life Sciences announced it had initiated a feasibility study of MDMA leveraging Catalent's proprietary Zydis ODT fast dissolve technology. Read more to learn what this means for the company, why this may be needed, and what experts are saying about Awakn.
Addiction Therapy Company Secures Major UK Endorsement (02/07/2023)
Pharmaceutical powerhouse Awakn has been awarded Innovative Licensing and Access Pathway (ILAP) access to UK markets. This classification, equivalent to FDA Breakthrough Therapy designation in the U.S., allows the company to expedite development growth in the region.
New Drug for Hearing Loss Approved for Clinical Trials (01/30/2023)
Plans call for an initial clinical trial to start in H1/23 in both the U.S. and the United Kingdom, where the biopharma recently received approval to proceed, noted an H.C. Wainwright & Co. report.
Biopharma Gains Another Shot on Goal With IND Approval (01/26/2023)
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.
Former Investment Officer of One of the World's Largest Sovereign Wealth Funds Shares His Current Focus (01/25/2023)
Streetwise Reports sat down with Øyvind Schanke, the chief investment officer of TD Veen and the former investment officer of one of the world's largest sovereign wealth funds as he shares his current focus.
Med Tech Co. Well-Poised for Revenue Growth This Year (01/25/2023)
New revenue sources already in place are expected to boost cash flow 72% over the next 12 months, noted an H.C. Wainwright & Co. report.
Biopharma Creating COVID Drug Gets US$8.2M From the DOD (01/24/2023)
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.
Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment (01/24/2023)
Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company.
Exploring Why The Economist Named this Biotech 'One To watch' in 2023 (01/23/2023)
As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023.
Telehealth Co. Expects More Growth in 2023 (01/20/2023)
Officials at telemedicine company Reliq Health Technologies say they expect to accelerate growth "significantly" in 2023, which could lead to a share buyback program.
Biopharma Co.'s Burn Tissue Removal Product Approved (01/04/2023)
Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report.
Which Precious Metal Has Chen Excited for 2023? (12/28/2022)
It's valued the world over as a precious metal, and now it's in demand for the green economy. Which element has asset manager Chen Lin looking forward to the New Year?
Tech. Analyst Says Pharma Co. Is at a Favorable Risk/Reward Ratio (12/28/2022)
Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company.
Target Price Boosted 400% on Biopharma Co. (12/27/2022)
The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report.
Biotech at Good Entry Point for Investors, Analyst Says (12/20/2022)
The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report.
Data on New Cell Therapy for LBCL Encouraging, Analyst Says (12/16/2022)
The biopharma behind the investigational treatment plans to advance it into a potentially pivotal clinical program next year, noted a BTIG report.
Why One Fund Owns 13% of This Small-Cap Pharma (12/12/2022)
Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease.
Biotech Co. Signs US$735M Deal (12/09/2022)
Entrada Therapeutics Inc. shares traded 18.5% higher yesterday after the company reported it entered a global development collaboration with Vertex Pharmaceuticals Inc. to develop cutting-edge intracellular Endosomal Escape Vehicle (EEV™) therapeutics for use in treating myotonic dystrophy type 1.
Biopharma Co.'s Shares Triple in Value on US$5B License Deal (12/07/2022)
Summit Therapeutics Inc. shares traded 194% higher yesterday after the company reported it entered into an in-license agreement with Akeso Inc. for its breakthrough bispecific antibody ivonescimab, which combines a blockade of PD-1 with an anti-VEGF into a single molecule designed to target cancer. Summit has agreed to pay Akeso an upfront payment of US$500 million, which it plans to finance via an equity rights issuance.
Biotech Co.'s Shares Soar to New 52-Week High (12/07/2022)
Prometheus Biosciences Inc. shares traded 170% higher to a new 52-week intraday high after the company reported positive results from two separate Phase 2 clinical studies for its PRA023, an anti-TL1A mAb used to treat inflammatory bowel disease. The company is actively planning to advance PRA023 into Phase 3 trials as a prospective treatment for ulcerative colitis and Crohn's disease in FY/23.
Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial (12/05/2022)
Shares of Anavex Life Sciences Corp. traded 36% higher Friday after the company reported that during a Phase 2b/3 clinical trial of patients diagnosed with early Alzheimer's disease, its ANAVEX®2-73 (blarcamesine) met both key primary and secondary endpoints and demonstrated significant reductions in clinical decline.
Target Price Boosted on Canadian Pharma Co. (11/30/2022)
This company, undergoing a business model shift, is doing well and remains Buy rated despite a weaker-than-expected Q3/22, noted a Research Capital Corp. report.
Biopharma Co. Now at a Bargain Price, Analyst Says (11/29/2022)
Recent share price weakness and a catalyst-rich next six months are good news for investors, noted a Research Capital Corp. report.
Major Contract and Faster Commercialization for Chemicals Co. (11/29/2022)
Since hitting the market on November 10, 2022, ASP Isotopes has been busy and has now announced a US$675 million-dollar contract. Expert Penny Queen shares this news and reviews why she still believes this company is worthwhile.
Expert Says Health Tech Co. Still in Good Spot To Buy (11/28/2022)
Technical analyst Clive Maund reviews the 1-year chart for Reliq Health Technologies to tell you whether he believes it is a Buy.
Biopharma Co. Trades to New 52-Week High (11/28/2022)
Shares of Axsome Therapeutics Inc. traded to a new 52-week high after the company reported its AXS-05 successfully met both the primary and key secondary endpoints in the Phase 3 ACCORD Alzheimer's disease agitation trial.
Pharma Co. Gains Approval for SARS-CoV-2 Drug (11/23/2022)
Shares of Japanese pharmaceutical firm Shionogi & Co. Ltd. traded nearly 13% higher yesterday after the company reported it received emergency regulatory approval from Japan's Ministry of Health, Labor, and Welfare for its Xocova® (ensitrelvir fumaric acid) tablets for use in treating SARS-CoV-2 infection.
Life Sciences Co. Exceeds Expectations in Q3/22 (11/22/2022)
During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report.
Q4/22 Catalysts Could Boost Undervalued Biopharma Stock (11/22/2022)
The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report.
Global Drug Co. Offers US$1.35B To Boost Hematology Assets (11/22/2022)
Imago BioSciences Inc. shares traded 104.5% higher yesterday to a new 52-week high after the company reported it entered into a definitive agreement to be acquired by Merck & Co. in an all-cash transaction for US$36.00 per share.
Blockchain Co. Signs Agreement With Insurance Co. (11/22/2022)
Global Compliance Applications Corp. signs an agreement with a South African insurance company to get into that country’s expanding cannabis industry.
FDA Awards Breakthrough Therapy Status for AMD Drug (11/21/2022)
Iveric Bio Inc. shares traded 25% higher Friday after the company reported that the U.S. FDA has granted breakthrough therapy designation for its avacincaptad pegol for use in the treatment of geographic atrophy secondary to age-related macular degeneration.
Pharma Co. Won't See Bump in Sales From New COVID Drug (11/18/2022)
The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report.
Biopharma Co. Hopes To Turn US$30M Into US$2B (11/17/2022)
CytomX Therapeutics Inc. shares traded 32% higher after the company reported it has formed a strategic research collaboration with Regeneron Pharmaceuticals Inc. to develop next-generation bispecific immunotherapies to treat multiple cancer tumor types.
Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data (11/16/2022)
4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration.
Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment (11/14/2022)
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon.
UK Co. Buys NARCAN® Nasal Spray Maker (11/14/2022)
Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met.
US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says (11/11/2022)
With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts.
Biologics Co. Doubles Revenue in Q3/22 (11/11/2022)
ADMA Biologics Inc. shares traded 27.5% higher yesterday after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million.
Pharma Co. Trades 200% Higher (11/10/2022)
Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma.
Medical Device Co.'s Q2/22 Results Better Than Expected (11/09/2022)
Along with improving its numbers during the quarter, this firm sold its first ultrasound ablation machines in North America, noted a Research Capital Corp. report.
Nine Stocks Expert Says Should Pique Your Interest (11/09/2022)
Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on.
Clean Nuclear Med Tech With Quantum Blue Sky (11/09/2022)
With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention.
Healthcare Firm Offers US$295M for Ophthalmology Co. (11/08/2022)
Shares of Oyster Point Pharma Inc. traded 38.5% higher yesterday after the firm reported it agreed to be acquired by Viatris Inc. for US$11.00 per share along with a contingent value right for a potential additional payment of up to US$2.00 per share.
Pharma Co. Signs Global License Deal for Eye Drops (11/08/2022)
Shares of Ocuphire Pharma Inc. traded 20% higher after the ophthalmology-focused biopharmaceutical firm reported it executed a global license agreement with FamyGen Life Sciences Inc. to develop and commercialize its Nyxol® Eye Drops for use in treating mydriasis, presbyopia, and night vision disturbances.
Organ Transplant Co.'s Q3 Revenues Rise 378% (11/04/2022)
Shares of medical technology firm TransMedics Group Inc. traded 24% higher to a new 52-week high after the company reported Q3/22 financial results highlighting a 378% YoY increase in net revenue and raised its FY/22 revenue estimates to US$80-85 million.
Telemedicine Co. Surges on Revenue News (11/04/2022)
As internet-enabled health care becomes more accepted in the wake of the pandemic, telemedicine company Reliq Health Technologies Inc. is seeing its revenue soar.
San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines (11/03/2022)
Arcturus Therapeutics Holdings Inc. shares traded 19% higher yesterday after the firm reported it entered a global partnership with CSL Seqirus to develop and commercialize self-amplifying mRNA vaccines worldwide.
Pharma Co. Earns Big Rewards from Global License Deal (11/02/2022)
Kiniksa Pharmaceuticals Ltd. shares traded 12% higher yesterday after the company reported Q3/22 financial results that included a 720% YoY increase in net revenue attributed to a combination of organic growth and increases in global licensing revenue.
Biopharma Co. Trades 39% Higher (11/01/2022)
Actinium Pharmaceuticals Inc. shares traded 39% higher yesterday to a new 52-week high after the firm reported topline data from its Phase 3 SIERRA study of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. During the pivotal trial, Iomab-B met its primary pre-established endpoint of durable complete remission or dCR of six months post-initial remission following a bone marrow transplant.
Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current (10/31/2022)
This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report.
Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial (10/28/2022)
Shares of Nuvalent Inc. traded 60% higher to a new 52-week intraday high after the company reported initial data from its Phase 1 ARROS-1 trial of NVL-520 demonstrating positive objective response rates in patients with ROS1-Positive non-small cell lung cancer.
Potential ROI With German Biopharma Co. Notable (10/27/2022)
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.
CRO Firm's Shares Rise on Q3 Earnings and Growth Prospects (10/26/2022)
Shares of full-service clinical contract research organization Medpace Holdings Inc. traded 37% higher yesterday after the company reported Q3/22 financial results that included a nearly 30% YoY increase in revenue.
Vaccine Co. Posts Positive Ph. 1/2 IPD Trial Results (10/25/2022)
Shares of Vaxcyte Inc. traded 61% higher yesterday to a new 52-week high after the company reported positive topline results from its Phase 1/2 study of VAX-24, its novel 24-valent pneumococcal conjugate vaccine candidate being developed to prevent invasive pneumococcal disease in adults 18 to 64 years of age.
Expert Says Buy Pharma Co. Stock 'as Soon as Possible' (10/25/2022)
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy its stock.
Biopharma Co. Shows Large Potential Return (10/21/2022)
Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report.
Robotic Surgical Device Co.'s Shares Rise on Q3 Earnings (10/20/2022)
Shares of Intuitive Surgical Inc. traded 9% higher yesterday after the robotic surgical device maker reported Q3/22 earnings that included an 11% YoY increase in revenue and a 13% YoY increase in its installed da Vinci Surgical System base.
Companies Use Blockchain To Connect Hemp Growers, Consumers (10/19/2022)
Industrial hemp is legal in all 50 states, and companies are working to get CBD, insulation, textiles, and biofuel made from it to the masses. These three companies hope their partnership will help connect the growers and buyers.
Biotech Co.'s Target Price Over Three Times Current (10/13/2022)
Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current.
Biopharma Co. Partners With Merck for Combo Drug Trial (10/12/2022)
With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report.
Biopharma Co.'s Shares Roll to New 52-Week High Price (10/12/2022)
Shares of DICE Therapeutics Inc. traded 62% higher yesterday and established a new 52-week intraday high after the company reported positive topline data from its Phase 1 DC-806 Psoriasis study.
Chen Reveals His Picks for Last Quarter (10/11/2022)
Asset manager Chen Lin's picks for the home stretch of 2022 include several biotechs and some precious metals companies.
US Firm Teams up With Leading Pharma Co. To Delay T1D Onset (10/07/2022)
Provention Bio Inc.'s shares traded 25% higher yesterday after the company reported it is joining forces with Sanofi U.S. to support the potential upcoming U.S. launch of its teplizumab for use in delaying the onset of clinical type 1 diabetes in at-risk patients. The U.S. FDA is expected to rule on the firm's Biologics License Application in mid-November 2022.
Biopharma Target Price 10 Times Current (10/06/2022)
Read to learn why ROTH Capital Partners gave Atai Life Sciences NV a Buy rating and a target price 10 times its current.
Biotech Co.'s Drug Showing 'Early Signs of Benefit' (10/06/2022)
With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report.
Trial Results of New Drug for An Eye Disease 'Encouraging' (10/06/2022)
The data suggest this treatment could be safer and more effective in treating proliferative vitreoretinopathy than compounded methotrexate, noted a Laidlaw & Co. report.
Co. Uses RNA Editing as Treatment for Rare Disease (10/03/2022)
The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report.
Interim Results From Phase 2b Trial Are 'Encouraging' (09/30/2022)
Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.
Biopharma Co. Awarded FDA Clearance for Advanced Solid Tumors Trial (09/30/2022)
Shares of oncology-focused biopharmaceutical company Immuneering Corp. traded 9% higher after the firm reported it received U.S. FDA clearance for its IND Application for a Phase 1/2a clinical trial of IMM-1-104 for use in treatment of advanced solid tumors with RAS mutations. The company expects to enroll the first patient in the study in Q4/22.
Pharma Co. Meets Primary Endpoint in Phase 3 Alzheimer's Trial (09/29/2022)
Shares of Eisai Co. Ltd. traded 58% higher yesterday after the company reported topline data from its global Phase 3 clinical study demonstrating that its lecanemab significantly met the primary and key secondary endpoints in reducing mild cognitive impairment due to Alzheimer's disease.
Biopharma Asks for Emergent Use in US of New COVID Drug (09/29/2022)
The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report.
Oncology Co.'s Shares Erupt on Signing Global License Deal (09/27/2022)
Shares of clinical-stage immuno-oncology company LAVA Therapeutics NV traded nearly 100% higher yesterday after the firm reported that it has entered into a global licensing agreement with Seagen Inc. to advance its LAVA-1223, a preclinical gamma delta bispecific T cell engager designed for use in the treatment of EGFR-expressing solid tumors.
Opportunity for Investors Found in Psychedelics Space (09/27/2022)
Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report.
US Biotech Firm Keeps Growing Revenue (09/26/2022)
Revenue last quarter was strong, and management expects to increase revenue 20% this fiscal year, noted a ROTH Capital Partners report.
Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating (09/23/2022)
To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report.
Analyst Says Buy Before Biotech Co.'s Clinical Trials (09/23/2022)
Argenx SE has "several upcoming catalysts," noted a Wedbush report.
Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World (09/21/2022)
The pandemic changed the way many people get their basic healthcare, giving a big opening to telemedicine companies like Reliq Health Technologies Inc.
FDA Approves Hearing Loss Drug for Child Chemo Patients (09/21/2022)
Shares of Fennec Pharmaceuticals Inc. traded 14% higher after the company reported it received approval from the U.S. FDA for its PEDMARK® (sodium thiosulfate injection) for use in reducing the risk of ototoxicity in pediatric patients who are undergoing or completed chemotherapy for non-metastatic solid tumors.
Dermatology Co.'s Target Price Much Higher Than Current (09/20/2022)
The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report.
Important Catalyst Expected Soon for Cancer Drug Co. (09/20/2022)
The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report.
Biopharma Co.'s Shares Rise on Phase 3 Migraine Trial Data (09/20/2022)
Satsuma Pharmaceuticals Inc. shares traded 12% higher to a new 52-week high after the company reported positive results from its Phase 3 long-term study of STS101 for use in acute treatment of migraine attacks. The company expects to receive further efficacy data from its Phase 3 SUMMIT trial in Q4/22, which it believes will support submission of an NDA with the U.S. FDA in Q1/23.
Second Trial of New Eczema Drug To Commence in Q4/22 (09/17/2022)
The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report.
FDA Grants Approval for Drug Improving Kidney Function (09/16/2022)
Shares of Mallinckrodt Plc. traded 28% higher yesterday after the company reported that the U.S. FDA has issued approval for its Terlivaz® (terlipressin) for injection for use in treating hepatorenal syndrome, a serious and life-threatening condition that is accompanied by rapid reduction in kidney function.
Price Target on US Biopharma Co. Boosted by $15 (09/15/2022)
The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report.
New Drug Shown To Help Patients With Desmoid Tumors (09/15/2022)
This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report.
NDA for Dry Eye Disease Drug on Track for Q4/22 Submission (09/15/2022)
This and the biopharma's other treatment candidates for ocular diseases are underappreciated, which translates to an investment opportunity, noted an Oppenheimer report.
Several Trials of Co.'s Fluid Pump To Read Out This Year (09/14/2022)
Positive topline data could boost the share price of this Swiss medical device firm, noted an H.C. Wainwright & Co. report.
Co. Advancing Drug Class With Broad Potential (09/13/2022)
This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report.
Biotech Co.'s Target Six Times Current Price (09/13/2022)
One Phase 2 clinical trial showing LSD reduced symptoms of anxiety bodes well for other studies of LSD in this indication. In light of this, Oppenheimer & Co. gave this biotech company a target price that is over six times its current share price.
Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better' (09/13/2022)
Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.
Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet (09/12/2022)
One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run.
Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise (09/12/2022)
Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report.
US Co. To Regain All Rights to Its AGHD Diagnostic Test (09/08/2022)
This is set to happen because the biopharma's commercialization partner recently terminated its agreement over the product, noted an H.C. Wainwright & Co. report.
Medtech Co. Meets Primary Endpoints in Ph. 3 Glaucoma Trials (09/08/2022)
Glaukos Corp.'s shares traded 18% higher yesterday after the company reported that in two separate Phase 3 trials, its iDose TR met its primary efficacy endpoints by lowering intraocular pressure in glaucoma patients.
Biopharma Co. Receives Approval From FDA Panel for ALS Drug (09/08/2022)
Amylyx Pharmaceuticals Inc.'s shares traded 51% higher after the company reported that a U.S. FDA advisory committee has voted to support approval of the firm's AMX0035 for use in treating amyotrophic lateral sclerosis. Although the committee's recommendation is not binding, it is expected that the decision will provide staunch support for approval of the firm's pending NDA for AMX0035, which has a target action date of September 29, 2022.
Biopharma Co. Transforming Injected Drugs Into Pills (09/07/2022)
This Israeli firm recently attracted the attention of the US-based financial institution, H.C. Wainwright & Co., which launched analyst coverage of it.
Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling (09/07/2022)
Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen.
Two Talks On New Cancer Drug Slated for Meeting This Week (09/06/2022)
The upcoming discussions pertain to a biopharma's clinical stage T-cell therapy as a treatment for solid tumors, noted a ROTH Capital Partners report.
Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study? (09/04/2022)
One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that's usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August.
Denmark Co. To Buy US Biopharma Co. for $1.1 Billion (09/02/2022)
Forma Therapeutics Holdings Inc. shares traded 51% higher yesterday after the company reported it agreed to be acquired by Denmark's Novo Nordisk A/S in an all-cash deal for $20.00 per share. With the acquisition, Novo Nordisk aims to expand its global presence in the treatment of rare blood disorders and sickle cell disease.
Expert Rates Pharma Co. An Immediate Buy (09/01/2022)
Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a study for the treatment of idiopathic pulmonary fibrosis and chronic cough.
FDA OKs Biopharma to Trial New Cell Therapy (08/30/2022)
Now with clearance, the firm plans to commence a Phase 1 study of its lead candidate in patients with lymphoma by the end of this year, noted an H.C. Wainwright & Co. report.
Pharma Co. Plans IND Filing for Dry Eye Disease Drug in Q4/22 (08/30/2022)
Shares of OKYO Pharma Ltd. traded 23% higher after the company reported it intends to submit an IND to the U.S. FDA for its OK-101 for treating dry eye disease in Q4/22. Together with its manufacturing partner, AmbioPharm Inc., the firm is now preparing to initiate a phase 2 clinical study in Q1/23.
Delay in New Drug Filing Now Could Yield Benefits Later (08/29/2022)
The developer of genetic medicines is taking six more months to conduct longer preclinical safety studies involving its lead therapeutic, noted an Oppenheimer report.
ACC Recommends Approved Drug for Lowering LDL (08/29/2022)
This same medicine is currently being evaluated in a global clinical trial from which topline results are expected in Q1/23, noted an H.C. Wainwright & Co. report.
Pharma Co. To Provide HHS With Smallpox Drug (08/29/2022)
Chimerix Inc. shares traded 8% higher after the company reported it has entered into a 10-year, $680 million contract with a U.S. Government health agency to deliver up to 1.7 million treatment courses of its TEMBEXA for use as a medical countermeasure for smallpox.
Biotech Co. Signs Option Agreement With Drug Co. to Find Ideal Ketamine Formula (08/26/2022)
A small biotech has taken further steps to deepen the intellectual property moat for its potentially revolutionary treatment for alcohol addiction. Find out which company it is and why one analyst has given it a CA$8 target price.
First Data Due by Year End 2022 From Study of New HAE Drug (08/24/2022)
Management's ongoing execution is raising the biopharma's profile among investors, noted an Oppenheimer report.
New Schizophrenia Drug Has Chance of Getting FDA Approved (08/24/2022)
The U.S. Food and Drug Administration's follow-up to the new drug application for this potential treatment suggests a possible green light based on unmet medical need, noted a BTIG report.
Hedge Fund Doubles Position in Biotech Co. (08/23/2022)
A Canadian hedge fund doubled its stake in a tiny biotech that demonstrated promising results in a study that used a former Sanofi drug called Ifenprodil to treat idiopathic pulmonary fibrosis and chronic cough. Find out the name of the company and why one analyst has given it a 12-month CA$25 target price — a 560% increase from the unit price in its recent placement.
Expert Sees Even More 'Good News' From Pharma Co. (08/23/2022)
Expert Clive Maund reviews the latest news with Algernon Pharmaceuticals Inc., including the recent successful closing of its financing.
Biotech Co. Has Multiple Shots on Goal (08/22/2022)
This developer of immunotherapies has a robust pipeline, several active clinical programs and, thus, numerous catalysts, noted an Oppenheimer report.
Price Target on Cancer Drug Co. Boosted (08/22/2022)
The price target was increased by 66% to reflect the full potential opportunity of the biopharma's drug candidate for hepatocellular carcinoma, a key driver going forward, noted an H.C. Wainwright & Co. report.
Drug Developer Initiates Ph. 3 STGD1 Trial (08/22/2022)
Shares of Belite Bio Inc. traded 19% higher after the company reported it has initiated a pivotal Phase 3 clinical study in the U.S. for its LBS-008 for use in treating Stargardt disease.
Biopharma Co. Gains FDA Approval for Oral MDD Drug (08/19/2022)
Shares of Axsome Therapeutics Inc. traded 39% higher after the company reported that the U.S. FDA granted approval for its AUVELITY™ making it the first oral N-methyl D-aspartate (NMDA) receptor antagonist authorized for treating major depressive disorder in adults.
Healthcare Co. Brings Treatment to Canadian Alcohol Addiction Market (08/18/2022)
One healthcare company in the U.K. is bringing its proprietary Ketamine-assisted treatment for Alcohol Use Disorder to Canada. It's the second deal the company has made with a North American clinic operator this week. Find out why this won't be the last one.
Biotech Co. To Receive 66% Funding From UK Gov. (08/17/2022)
Expert Clive Maund reviews the latest update with Awakn Life Sciences Corp., including its recent rise in stock volume and the announcement that the company is to receive 66% funding support from the UK government for the development of its ketamine-assisted therapy treatment for alcohol use disorders.
Life Sciences Co. Gets Big Order for Livestock Feed Additive (08/16/2022)
This sale indicates the firm is continuing to forge a pathway into one of its large target markets, noted a Noble Capital Markets report.
Co. Pursuing Ketamine for Addiction Forms Partnership (08/16/2022)
In landing this first licensing deal, the life sciences firm "shows good progress towards a potentially high-margin business," noted a Stifel report.
Co. Provides Ground-Floor Opportunity in Precision Oncology (08/15/2022)
Nuvectis Pharma Inc recently announced quarterly financial results and is continuing to advance its precision oncology programs. H.C. Wainwright & Co. LLC advised in an earnings update that the firm offers significant upside potential as it is rapidly advancing its drug candidates through clinical development and is looking for ways to expand to markets outside of the U.S. H.C. Wainwright stated that it is reiterating its Buy rating and $21 price target for Nuvectis Pharma.
HSCT/Gene Therapy Co. Sees Many Positive Catalysts in Q422 (08/15/2022)
Hematopoietic stem cell transplantation (HSCT) and gene therapy firm Magenta Therapeutics Inc. recently announced updates related to two of its leading clinical programs. BTIG LLC advised in a research update that it expects Magenta to release updated clinical data from its MGTA-117 and MGTA-145 programs in Q4/22, which will serve as key catalysts for the company. BTIG stated it is reiterating its "Buy" rating and $6/share price target on Magenta Therapeutics.
Biotech Co. Nearing Milestones for HBV Drugs (08/15/2022)
Arbutus Biopharma Corp. presented clinical data to an international liver disease conference showing that its AB-729 continues to deliver strong reductions in HBsAg. The company is now conducting three separate combination therapy studies of its AB-729 and expects to achieve important milestones when the initial data readouts are released in H2/22. H.C. Wainwright & Co. affirmed its Buy rating for Arbutus Biopharma and adjusted its price target to $7.50.
Healthcare Co. Enters US Alcohol Addiction Treatment Market (08/15/2022)
One analyst says this healthcare co. has the opportunity to generate attractive CAPEX-light, high margin SaaS-like recurring revenues, which investors are currently getting for free, after the biotech firm entered the US market for alcohol addiction treatment through off-label licensing deals with a network of treatment clinics.
Expert Expects Life Science Co. To Do Exceptionally Well (08/15/2022)
Avivagen is an early-stage life sciences company with a patented product for immune support that causes dramatic and profitable improvements in livestock. They have been increasing their sales and market penetration at a dramatic rate, and I believe them to be at an inflection point. Research coverage is expecting a 7x return.
Firm Sees Boost in Sales of Health Chewable for Dogs (08/15/2022)
Recent orders from Avivagen Inc. are helping the developer of this product build a recurring revenue stream, noted a Noble Capital Markets report.
Diagnostics Co. Secures Global Deal for Resistant Bacteria ID Kit (08/15/2022)
Accelerate Diagnostics Inc. shares traded 25% higher after the company reported Q2/22 earnings and announced it entered into a commercial agreement with Becton, Dickinson and Co. that will allow it to deliver rapid antimicrobial identification and susceptibility diagnostics to clinicians and patients worldwide.
Feedstock Additive Co. Gets Massive Order for Brazil Market (08/11/2022)
The widespread use of antibiotics in animal feeds, as well as over-prescription by physicians for therapeutic treatment of human infections, is leading to a growing resistance to antibiotics that is killing close to 1 million people each year. One company believes it has developed at least part of the solution through a beta carotene food additive that boosts immunity and contributes to better overall health.
Testing Confirms Drug Candidate Differs From Peers (08/10/2022)
Biotech ProMIS Neurosciences Inc.'s monoclonal antibody in development for Alzheimer's disease boasts a "unique" binding profile that could be "important to its clinical success," noted a Leede Jones Gable report.
Demand for Co.’s Antibiotic Free Animal Feed Is Raising (08/10/2022)
With consumers moving away from artificial meat products and other preservatives, Avivagen Inc.'s antibiotic free animal feed seems to be just what they're looking for. With orders coming in and demand raising, expert Clive Maund shares his view on the potential of this life science company.
Pharma Co. Achieves Record Sales of LEMS Drug in Q2 (08/10/2022)
Shares of Catalyst Pharmaceuticals Inc. traded 24% higher to a new 52-week high after the company reported that in Q2/22 net product revenues from sales of its FIRDAPSE® increased 57.7% YoY to $53.0 million. FIRDAPSE® has been approved by both the U.S. FDA and Health Canada as a treatment for adult patients with Lambert-Eaton myasthenic syndrome, a rare autoimmune disease in which a person's immune system attacks its body's own tissues at the neuromuscular junction.
Cardiovascular Device Co. On Pace to Double Revenue in FY22 (08/09/2022)
Shares of Shockwave Medical Inc. traded 17% higher to a new 52-week high after the company advised that it posted a 116% YoY increase in revenue during Q2/22 and raised the midpoint for its FY/22 revenue guidance by $25 million to $465-475 million.
Biotech Co. Awakes To Good News (08/06/2022)
Awakn Life Sciences Corp.'s rating went to an Immediate Speculative Buy after it received substantial funding from the UK government. Expert Clive Maund shares his thoughts on the development.
Biopharma Co. Planning BLA for DMD Drug (08/05/2022)
Sarepta Therapeutics Inc. recently announced that it intends to submit a BLA to the U.S. FDA for its SRP-9001, a gene therapy to treat Duchenne muscular dystrophy. Equity research firm BTIG LLC advised in a research update that SRP-9001 seems to have met the necessary criteria for receiving accelerated approval and it expects an AdCom will be established shortly. BTIG stated that it rates Sarepta Therapeutics as a "Buy" and has a $125 price target for the company's shares.
SRT Device Maker's Revenues Rise 124% in Q2 (08/05/2022)
Sensus Healthcare Inc.'s shares traded 30% higher after the company reported it achieved a 124% YoY increase in revenue in Q2/22. The company advised that demand continues to remain strong for its superficial radiation therapy (SRT) devices which provide minimally invasive and non-surgical alternatives for non-melanoma skin cancer & keloid removal.
Environmental Tech Co. Builds up to a Major Bull Market (08/04/2022)
After a few weeks of observation, expert Clive Maund believes Bion Environmental Technologies Inc. may be due for a major uptrend and is building up to a major bull market.
Ins. Provider to Offer Med Tech Co.'s CGM to its 45M Members (08/04/2022)
Shares of Senseonics Holdings Inc. traded 31.5% higher yesterday after the company reported that Elevance Health (formerly Anthem) has approved coverage of its Eversense® E3 implantable continuous glucose monitor to its forty-five million covered members.
ChemoCentryx Shares Double on $4B Cash Bid from Amgen (08/04/2022)
Shares of ChemoCentryx Inc. traded 110% higher after the company reported it agreed to be acquired by Amgen Inc. for $52.00 per share in an all-cash deal valued at $4 billion. With the purchase, Amgen aims to cement its leadership position in inflammation and nephrology with the addition of ChemoCentryx's TAVNEOS® (avacopan) which the U.S. FDA approved late last year to treat ANCA-associated vasculitis, a serious autoimmune disease.
MRI Device Maker's Earnings Come In at High End of Forecasts (08/03/2022)
IRadimed Corp. reported Q2/22 financial results that were modestly higher than expected. ROTH Capital Partners LLC advised in a research update that based on the company's higher revenues, improved margins and disciplined cost control measures it is maintaining its Buy rating on IRadimed and raising its price target to $42/share (up from $40).
Expert Says Biotech Co. Is a ‘Strong Buy’ After Phase 2 Study (08/02/2022)
Expert Clive Maund gives his assessment of biotech Algernon Pharmaceuticals Inc. after its Phase 2 study of Ifenprodil.
Expert Believes Health Co. Blooms With Opportunity (08/02/2022)
Expert Clive Maund touches on the latest news with Bloom Health Partners Inc. from the enthusiastic buying toward the end of June to whether he believes the health company is still bullish.
Tech Co. ‘Right at the Point of Breakout' (08/02/2022)
BioLargo Inc. seemed to be very close to breaking out of its tight trading range on July 20, 2022, after remaining in the same place for a month. Expert Clive Maund goes over this update and his assessment of the company after this news.
Study Review Shows Greater Promise for Biopharma Co.'s Cough Treatment (08/01/2022)
After Algernon Pharmaceuticals Inc.'s Ifenprodil treatment for chronic cough was reviewed in a Phase 2 analysis, analysts at Research Capital Corp. noted that it is maintaining its Speculative Buy rating on the company.
Drug Candidate Repairs Motor/Sensory Function in Stroke (07/29/2022)
Shares of NervGen Pharma Corp. traded 28% higher yesterday after the company reported that, in a landmark pre-clinical animal study, its NVG-291-R demonstrated significant functional repair to damage from ischemic stroke seven days following the event.
Additional Study Review Reveals Patients Coughed Much Less (07/28/2022)
A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought.
Biotech Co. Granted New Patent for Breast Cancer Vaccine (07/27/2022)
Last Thursday, Anixa Biosciences Inc. announced that the USPTO granted an extension for the firm's patented breast cancer vaccine technology. H.C. Wainwright & Co. LLC advised that this action strengthens the company's IP portfolio and therefore it is reiterating its Buy rating on Anixa.
Biopharma Co. Signs Exclusive License Deal for Ricin Antigen (07/27/2022)
Shares of Soligenix Inc. traded 8% higher after the company reported it formed a strategic global partnership to supply SERB Pharmaceuticals with its novel ricin antigen for use in developing a therapeutic treatment against ricin poisoning.
Biomedical Firms Merger Makes Programming Cells Easier (07/26/2022)
Shares of Zymergen Inc. traded 16% higher after the company reported it agreed to be acquired by Ginkgo Bioworks Inc. in an all-stock transaction valued at $300 million.
Cancer Co.'s Price Target Adjusted After Reverse Stock Split (07/25/2022)
Late clinical-stage biopharmaceutical company Cellectar Biosciences Inc. very recently underwent a one for 10 reverse stock split. ROTH Capital Partners LLC advised that it has adjusted its forward projections for the firm and adjusted its 12-month price target to $40/share.
Radiotherapy Co. On-Track With Two Clinical Trials (07/24/2022)
Plus Therapeutics Inc. is developing novel radiotherapy treatments for several rare cancer targets including glioblastoma and leptomeningeal metastases. H.C. Wainwright & Co. advised in a research note that it is reiterating its Buy rating on the company as it expects that upcoming data from two key trials for the firm's RNL-based treatments could provide a major catalyst for the stock in H2/22.
Pro Athlete Benefits From Co.'s Wound Treatment Device (07/22/2022)
Shares of SANUWAVE Health Inc. traded 12% higher after the company reported it successfully treated legendary football player Jim McMahon Jr. with its ENERGY FIRST system.
Medical Device Firm Maintains Growth Momentum in Q2/22 (07/21/2022)
electroCore Inc.'s Q2/22 and H1/22 revenues are up quarter over quarter and year over year, respectively, and the upward trend is expected to continue through year-end 2022, noted an H.C. Wainwright & Co. report.
Amazon Makes $3.9B Bid for Virtual Primary Care Co. (07/21/2022)
Shares of One Medical traded nearly 70% higher after the company reported it agreed to be acquired by Amazon Inc. for $18.00 per share in an all-cash deal valued at $3.9 billion.
Biotech Co.'s Phase 3 Trial First to Get Grant (07/20/2022)
A revenue-generating junior biotech company based in the U.K. has become the first public company to be approved for a government grant to fund most of a Phase 3 study exploring the use of psychedelics to treat alcohol use disorder. It could be a catalyst for the share price.
Drug Repurposing Co. Provides Opportunity for High Rewards (07/20/2022)
Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough that met its endpoint and demonstrated promising initial efficacy. Research Capital Corp. advised that it is maintaining its CA$25.00/share price target and "Speculative Buy" rating on the company.
Trial Results Show New Drug Improves Dry Eye Symptoms (07/19/2022)
These study data from Aldeyra Therapeutics Inc. solidified the therapeutic's path to filing a new drug application, potentially in Q3/22, noted an H.C. Wainwright & Co. report.
Biopharma Co. Looks to Expand New Drug Label Down the Road (07/18/2022)
ScPharmaceuticals Inc. just released topline results from a Phase 2 pilot study supporting the drug developer that is pursuing the expansion of its new drug label, noted an H.C. Wainwright & Co. report.
Healthcare Co.’s Psychedelic-Assisted Treatments Have ‘Blockbuster Drug Potential’ (07/15/2022)
Psychedelic-assisted therapy has shown in a clinical trial that it can help patients with alcohol use disorder (AUD) or alcoholism. One company hopes to bring its treatments to clinics throughout Europe and become the go-to standard of care for AUD.
Pharma Co. Reduces Mortality Rates by 70% in ALS Trial (07/15/2022)
Shares of Clene Inc. traded 38% higher yesterday after the company reported that its CNM-Au8 was shown to significantly decrease mortality in its RESCUE-ALS long-term extension trial.
Healthcare Co. Wants Share of $17.5B Addiction Treatment Industry (07/14/2022)
One healthcare co. is currently rated a Buy and is making a push for a share of the $17.5-billion addiction treatment industry after a recent study showed its psychedelic-assisted psychotherapy treatment showed a significant decrease in alcohol use, noted a Maxim Group equity research report.
Biopharma Co. Posts 17% BMI Reduction in Ph. 2 Trial (07/14/2022)
Shares of Rhythm Pharmaceuticals Inc. rose by over 30% after the company posted positive interim results from its Phase 2 clinical study of setmelanotide in hypothalamic obesity. The data shows that after 16 weeks of treatment with setmelanotide, patients experienced a 17.2% mean reduction in BMI and a mean weight loss of 15.8%.
Analyst Sees 'Attractive Long-Term Economics' for Healthcare Co. (07/13/2022)
One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments.
Three Analysts Like Healthcare Co.'s Upside (07/11/2022)
It is difficult to get three people to agree on anything, let alone three investment analysts. But that is precisely the case with one junior biotech company that has shown in a clinical trial that its ketamine-assisted therapy for alcohol use disorder (AUD) is three times more effective than the current standard of care.
Pharma Looks To Improve Potential Psychedelic Stroke Drug (07/11/2022)
Can a psychedelic compound help you heal after a stroke? This biopharmaceutical company hopes it can and plans to start Phase 1 trials this September.
New Drug Is Shown to Help Stopped or Reduced Bile Flow (07/10/2022)
Albireo Pharma Inc.'s positive Phase 3 trial results indicate the medication would afford patients clinical and quality of life benefits, noted an H.C. Wainwright & Co. report.
New DMD Drug Yields 'Compelling' Data (07/09/2022)
A statistical reanalysis of trial results from Sarepta Therapeutics Inc. shows improved patient function, noted an Oppenheimer report.
Amended Agreement to Benefit Two Biotech Firms (07/08/2022)
In the new arrangement between Beam Therapeutics Inc. and Verve Therapeutics Inc. each of the companies grants the other an exclusive license, one to a base editing target, the other to a gene delivery technology, noted a Wedbush report.
Co. Makes Financing Deals Around Two of Its Approved Drugs (07/07/2022)
The agreements include milestone payments based on future revenue from sales of the biopharma Blueprint Medicines Corp.'s therapies, noted a Wedbush report.
Strong Data Suggest FDA Will Approve New Lymphoma Drug (07/06/2022)
A green light is expected for the treatment after its developers submit a biologics license application for it, planned for H2/22, noted an H.C. Wainwright & Co. report.
The FDA Is Expected to Approve New Narcolepsy Drug (07/05/2022)
Avadel Pharmaceuticals Plc., the biopharma company behind this treatment, is currently undervalued and rated Outperform, noted an Oppenheimer report.
Laser Device Co. Gains FDA Approval for Next-Gen Catheter (07/05/2022)
Ra Medical Systems Inc. shares traded 36% higher after the firm reported it received U.S. FDA 510(k) clearance for its DABRA 2.0 Catheter. The DABRA 2.0 is incorporated into the company's DABRA Excimer Laser System which is used by vascular surgeons in procedures to treat lower extremity and peripheral vascular disease.
Trial of New Alzheimer's Drug Slated for Early 2023 (07/01/2022)
The biotech behind this product candidate differentiates itself from competitors with its approach to developing selective antibody therapies, noted an Argus Research Co. report.
MedTech Co.'s Shares Maneuver Higher on Q1 Revenue Growth (07/01/2022)
Shares of personalized, member-focused healthcare solutions company Accolade Inc. traded 29% higher after the company reported financial results for Q1/23 highlighting a 44% YoY increase in revenue and significant improvements in adjusted gross margin.
Chen's Top Picks for Q3 (06/30/2022)
Need to know where to go in these turbulent times? Asset manager Chen Lin has some ideas with his top picks for the third quarter.
BioNTech and Pfizer Secure $3.2B Vaccine Order from US Govt. (06/30/2022)
Shares of BioNTech SE traded 5% higher after the company together with its partner Pfizer Inc. reported that the two firms have agreed to provide 105 million 30 µg, 10 µg and 3 µg new doses of the SARS-Co-V2 vaccine to the U.S. government in a contract valued at $3.2 billion. The agreement includes a provision allowing the U.S. government to purchase up to an additional 195 million doses, which if exercised would increase the grand total to 300 million doses.
New Alzheimer's Drug Shows Promise as Monotherapy (06/29/2022)
Athira Pharma Inc.'s treatment with this small molecule alone resulted in improvements related to both primary and secondary endpoints, indicating pharmacological activity, noted a BTIG report.
Dental & Animal Health Supplier Posts 10% Yearly Sales Gains (06/29/2022)
Shares of Patterson Companies Inc. traded 11% higher after the dental supply and animal health products distributor reported Q4/22 and FY/22 financial results highlighting a 9.9% increase in annual sales and an expansion in operating margins.
Small Cap Joins With Japan Pharma to Advance Next Generation Cancer Treatment (06/28/2022)
Shares of Sutro Biopharma Inc. traded 21% higher after the company announced it entered into a global collaboration agreement with Japan's Astellas Pharma to advance three novel immunostimulatory antibody-drug conjugates.
Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression (06/27/2022)
In this trial, slated to commence next quarter, the biopharma will test the efficacy of its version of the psychedelic compound in this mental health indication, noted a ROTH Capital Partners report.
Approval Likely of New Gel for Skin Condition, Analyst Says (06/27/2022)
The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report.
EU Biopharma Co. Makes $247M Bid for US Oncology Co. (06/27/2022)
Epizyme Inc. shares traded 55% higher today after the company reported that it agreed to be acquired by Ipsen S.A. of France for $1.45 per share along with a contingent value right of $1.00 per share.
Gene Therapy Co. Releases Data From Huntington's Study (06/23/2022)
Shares of uniQure N.V. traded 26% higher after the company released 12-month treatment data from the low-dose cohort in its Phase 1/2 Huntington's disease clinical trial.
PE Firm to Take Health Tech Co. Private in $1.1B Deal (06/22/2022)
Shares of healthcare technology and services firm Convey Health Solutions Holdings Inc. traded 138% higher after the company reported it received a proposal from majority shareholder TPG Inc. to take the company private. TPG has offered to buy all outstanding shares in Convey that it does not already own for $10.50 per share in cash.
Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial (06/22/2022)
Shares of Biomea Fusion Inc. traded 14% higher after the company reported it dosed the first Multiple Myeloma patient in its Phase 1 COVALENT-101 r/r acute leukemia trial.
Results of Dermatitis Clinical Trial Due This Summer (06/21/2022)
Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report.
New Positive Data Seem to Support Drug Label Expansion (06/21/2022)
Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report.
New Drug for Heart Failure on Path to Approval, Analyst Says (06/20/2022)
The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report.
NFL Player Teams With Biopharma Co. to Help SCD Patients (06/17/2022)
Shares of Global Blood Therapeutics Inc. traded 12% higher after the company reported it has teamed up with New York Jets running back Tevin Coleman and his family to promote education and to offer hope and support to families affected by sickle cell disease.
Dispute Between Biopharma Cos. To Be Resolved by Sept. 30 (06/16/2022)
The arbitration court extended the original deadline for a decision in this case of an alleged breach of contract between TRACON Pharmaceuticals Inc. and I-Mab Biopharma, noted an H.C. Wainwright & Co. report.
Biotech Co. Advances 3 New Clinical Stage Assets (06/16/2022)
Ocugen Inc.'s new diverse product candidates include a COVID vaccine, a gene therapeutic for retinitis pigmentosa, and a cell therapy to prevent osteoarthritis, noted a ROTH Capital Partners report.
Healthcare Tech Firm Improves Earnings and Cash Flow in Q3/22 (06/14/2022)
These changes earned Reliq Health Technologies Inc. an upgrade in overall rating by independent investment research and advisory firm, Jefferson Research.
Investors Gain a Breath of Fresh Air From Ph. 3 CS Trial Results (06/13/2022)
Optinose Inc. shares traded 40% higher after the company reported positive top-line data from its Phase 3 ReOpen2 Trial of XHANCE for use in treating chronic sinusitis without nasal polyps.
Biopharma Co.'s New Diabetes Drug Candidate Shows Promise (06/10/2022)
Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models.
New Drug for Peanut Allergy in Toddlers Shown Safe and Effective (06/10/2022)
The response rate to DBV Technologies SA's drug patch in the recent Phase 3 clinical trial was statistically significant, which bodes well for the company as there is currently no approved therapy for children with this condition.
Biotech Co.'s Shares Soar on Ph. 2 Hematology Trial Results (06/10/2022)
Cogent Biosciences Inc. shares traded 70% higher after the firm reported positive clinical data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM), a severe hematologic disorder.
Good Chance FDA Will Greenlight Solution for Dry Eye Disease (06/09/2022)
Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report.
Small Biomedical Device Co. Is Ready to Take a Big Step Into Success (06/08/2022)
After weathering some major setbacks, PetVivo Holdings Inc. is stepping it up. With their new product for osteoarthritis and the team's perseverance, they may soon show themselves as a diamond in the rough.
Biopharma Co. Meets Primary Endpoints in ARDS Trial (06/08/2022)
MediciNova Inc. shares traded 9% higher after the company released top-line data from its Phase 2 study of MN-166 (ibudilast) in hospitalized COVID-19 patients deemed to be at elevated risk for acute respiratory distress syndrome. In the study, MN-166 demonstrated significant decreases in respiratory failure.
FDA Approves Co.'s New Medical Grade Air Hygiene Device (06/07/2022)
Shares of AeroClean Technologies Inc. traded 150% higher after the company reported it received 510k clearance from the U.S. FDA for its Pūrgo™ medical-grade indoor air purification technology that uses UV-C LEDs to eradicate airborne bacteria, fungi, and viruses, including COVID-19.
Approved Drug Shows Promise in Follicular Lymphoma (06/06/2022)
Comparison of new and previous clinical trial data shows improved efficacy, noted a Wedbush report.
FDA Approval of Drug Could Be on the Way (06/03/2022)
"We continue to see good overall odds of ultimate approval" despite the current delay, noted an H.C. Wainwright & Co. report, regarding Verrica Pharmaceuticals topical drug for molluscum contagiosum, a viral skin infection.
Bristol Myers to Buy Precision Oncology Co. (06/03/2022)
Turning Point Therapeutics Inc. shares traded 116% higher after the company reported it entered into a definitive agreement to be acquired by Bristol Myers Squibb Co. in an all-cash transaction for $76.00 per share.
Precision Oncology Co. Signs $1.325B Licensing Deal (06/02/2022)
Repare Therapeutics Inc. shares traded more than 50% higher after the company reported it entered into a worldwide license and collaboration agreement with Roche AG for its anti-tumor drug camonsertib (RP-3500). The agreement includes an upfront payment of $125 million and up to an additional $1.2 billion in development, sales and royalties if certain milestones are achieved.
Important Data for COVID Drug Candidate Due This Month (06/02/2022)
The "update should be important for determining EDP-235's potential to tap into this large market," noted a ROTH Capital Partners report.
More Archives
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
